# Acumen Posts Q3 GAAP Loss Per Share 2 Cents Below Estimate

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/40999
Published: 2026-10-26T11:58:48.000Z
Updated: 2026-10-26T11:58:48.000Z
Section: Business

> Cash, cash equivalents and marketable securities totaled $78.6 million on Sept. 30, 2026.

Acumen Pharmaceuticals expects its $78.6 million balance to support clinical and operating activities into early 2027 after posting a third-quarter GAAP loss of 35 cents per share, 2 cents narrower than estimated.

The balance included cash, cash equivalents and marketable securities as of Sept. 30, 2026.